AVI BioPharma

Contact
avibio.com
+1425354-5038

AVI BioPharma, Inc.

3450 Monte Villa Parkway
98021 Bothell
USA
+1425354-5038
avibio.com
Contact
Profile News
Contact

About AVI BioPharma

As global leaders in the field of RNA-based therapeutics, AVI BioPharma, Inc. is aggressively leveraging our differentiated and proprietary RNA-based antisense platforms to discover and advance innovative therapeutic candidates.

Read more about AVI BioPharma
Facts about AVI BioPharma
  • Focus : Manufacturer
  • Industry : Pharma

News about AVI BioPharma

AVI BioPharma

23-Aug-2010 | science

Novel 'antisense' therapies protect primates from lethal Ebola and Marburg viruses

New studies show that treatments targeting specific viral genes protected monkeys infected with deadly Ebola or Marburg viruses. Furthermore, the animals ...

Read news
AVI BioPharma

25-Jan-2005 | business & finance

AVI BioPharma Announces $24 Million Direct Equity Placement

AVI BioPharma, Inc. announced that it has entered into definitive agreements with several institutional investors for the purchase of 8 million shares of ...

Read news
AVI BioPharma

21-Jan-2005 | people

AVI BioPharma Appoints Vice President of Cardiology

AVI BioPharma, Inc. announced that Joseph B. Horn has joined the company as vice president of cardiology. Horn joins AVI from Cook, Inc., where he most ...

Read news
AVI BioPharma

02-Nov-2004 | research and development

AVI BioPharma and USAMRIID Announce NeuGene Antisense Drug Demonstrates Efficacy Against Ebola Virus

AVI BioPharma, Inc. , and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) announced positive results from experiments testing ...

Read news
AVI BioPharma

13-Sep-2004

AVI BioPharma Presents Antisense Approach to Transplant Acceptance By Regulating Activated Lymphocytes

AVI BioPharma, Inc. (Nasdaq: AVII), today announced it presented data on its NeuGene® antisense approach to transplant acceptance at the 20th International ...

Read news
AVI BioPharma

25-Aug-2004 | science

AVI BioPharma Announces Dengue Virus Collaboration With CDC

AVI BioPharma, Inc. announced it has signed a Cooperative Research and Development Agreement (CRADA) with the Centers for Disease Control and Prevention ( ...

Read news
AVI BioPharma

12-Aug-2004 | business & finance

AVI BioPharma Announces NeuGene Antisense Collaboration With USAMRIID on Biodefense Agents

Portland. AVI BioPharma, Inc. announced it has signed a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Medical Research ...

Read news
AVI BioPharma

02-Jun-2004 | science

AVI BioPharma's NeuGene Antisense Shows Inhibition of Dengue Virus

PORTLAND, Ore. - AVI BioPharma, Inc., presented results of a study showing inhibition of dengue virus with its NeuGene® antisense compounds at the Seventh ...

Read news
Show more news about AVI BioPharma

Here you will find AVI BioPharma, Inc.